BCA
PTLA

Berman Capital Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Berman Capital Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-41
Closed – – 1780
2019
Q4 		$0 Sell
41
-28
-41% -$772 ﹤0.01% 1603
2019
Q3 		$1K Buy
69
+28
+68% +$786 ﹤0.01% 1418
2019
Q2 		$1K Hold
41
– – ﹤0.01% 1436
2019
Q1 		$1K Buy
+41
New +$1.18K ﹤0.01% 1316

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Berman Capital Advisors's PTLA Position: Q1 2020 in Review

Berman Capital Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 41 shares.

Berman Capital Advisors first reported a position in PTLA in Q1 2019 and held it in 4 quarters. The position peaked at $1K in Q3 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

  • Berman Capital Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Berman Capital Advisors sold 41 Portola Pharmaceuticals, Inc. shares in Q1 2020.
  • Berman Capital Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q1 2019 and held it in 4 quarters.
  • Berman Capital Advisors's Portola Pharmaceuticals, Inc. position peaked at $1K in Q3 2019.
  • 187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Berman Capital Advisors's 13F filing for Q1 2020, filed 14 May 2020.